Future work developing ARA, or derivatives, as an α7 nAChR-selective therapeutic delivery system could have applications for the treatment of neurological conditions involving the α7 nAChR, including Alzheimer's disease and major depressive disorder (Mineur et al. 2018; Fernandes 2018; Ren et al. 2020; Martin et al. 2004). The gene discussed is CHRNA7; the disease is early-onset autosomal dominant Alzheimer disease.